| A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect (NCT05486195) | AbbVie | 2019-03-14 |
| A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (NCT03671148) | AbbVie | 2019-03-07 |
| Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA) (NCT03779841) | AbbVie | 2019-03-01 |
| Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation (NCT03868163) | AbbVie | 2019-02-28 |
| Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension (NCT03850782) | AbbVie | 2019-02-28 |
| A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis (NCT03737812) | AbbVie | 2019-02-27 |
| A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation (NCT03873857) | AbbVie | 2019-02-25 |
| A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis (NCT03738397) | AbbVie | 2019-02-21 |
| Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (NCT03821935) | AbbVie | 2019-02-21 |
| A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice (NCT03659669) | AbbVie | 2019-02-10 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis (NCT03646604) | AbbVie | 2019-01-31 |
| A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (NCT03725202) | AbbVie | 2019-01-24 |
| A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (NCT03706040) | AbbVie | 2018-12-27 |
| A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis (NCT03737851) | AbbVie | 2018-12-11 |
| A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis (NCT03653026) | AbbVie | 2018-12-06 |
| The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone (NCT03739203) | AbbVie | 2018-11-10 |
| Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone (NCT03738215) | AbbVie | 2018-11-09 |
| A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (NCT03661138) | AbbVie | 2018-10-27 |
| A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) (NCT03695237) | AbbVie | 2018-10-24 |
| A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer (NCT03639194) | AbbVie | 2018-10-24 |
| A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. (NCT03539744) | AbbVie | 2018-10-22 |
| A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia (NCT03625505) | AbbVie | 2018-10-18 |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer (NCT03539536) | AbbVie | 2018-10-10 |
| A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis (NCT03682705) | AbbVie | 2018-10-08 |
| An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs (NCT03740230) | AbbVie | 2018-09-26 |
| A Long-Term Study of Rovalpituzumab Tesirine (NCT03543358) | AbbVie | 2018-09-10 |
| A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis (NCT03398135) | AbbVie | 2018-08-28 |
| Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (NCT03569293) | AbbVie | 2018-08-13 |
| A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy (NCT03406156) | AbbVie | 2018-08-10 |
| A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (NCT03568318) | AbbVie | 2018-08-09 |
| UNITE Study: Understanding New Interventions With GBM ThErapy (NCT03419403) | AbbVie | 2018-07-30 |
| Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia (NCT03593213) | AbbVie | 2018-07-30 |
| A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis (NCT03219437) | AbbVie | 2018-07-30 |
| A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) (NCT03607422) | AbbVie | 2018-07-27 |
| A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT03484520) | AbbVie | 2018-07-23 |
| Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (NCT03518047) | AbbVie | 2018-07-19 |
| A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors (NCT03595059) | AbbVie | 2018-07-13 |
| A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features (NCT03573297) | AbbVie | 2018-06-15 |
| A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection (NCT03219216) | AbbVie | 2018-06-06 |
| A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST) (NCT03505892) | AbbVie | 2018-06-05 |
| A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT03441555) | AbbVie | 2018-05-30 |
| Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases (NCT03339089) | AbbVie | 2018-05-18 |
| Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis (NCT03478787) | AbbVie | 2018-05-08 |
| A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®) (NCT03383263) | AbbVie | 2018-05-04 |
| A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (NCT03518034) | AbbVie | 2018-05-03 |
| A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment (NCT03374917) | AbbVie | 2018-04-18 |
| Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 (NCT03413319) | AbbVie | 2018-04-17 |
| A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma (NCT03314181) | AbbVie | 2018-04-02 |
| A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (NCT03345823) | AbbVie | 2018-03-21 |
| A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab (NCT03368859) | AbbVie | 2018-03-20 |
| A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer (NCT03360006) | AbbVie | 2018-03-16 |
| Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer (NCT03334487) | AbbVie | 2018-03-15 |
| Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia (NCT03415035) | AbbVie | 2018-03-09 |
| A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis (NCT03398148) | AbbVie | 2018-03-07 |
| Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients (NCT03339102) | AbbVie | 2018-01-25 |
| An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) (NCT03391765) | AbbVie | 2018-01-24 |
| Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (NCT03310190) | AbbVie | 2018-01-10 |
| A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) (NCT03316794) | AbbVie | 2018-01-04 |
| A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) (NCT02955212) | AbbVie | 2018-01-03 |
| Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN (NCT03386513) | AbbVie | 2018-01-02 |
| A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain (NCT03343067) | AbbVie | 2017-12-27 |
| A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment (NCT03104413) | AbbVie | 2017-12-18 |
| COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel (NCT03362879) | AbbVie | 2017-12-14 |
| A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies (NCT03345849) | AbbVie | 2017-12-07 |
| Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting (NCT03342144) | AbbVie | 2017-12-04 |
| A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy (NCT03345836) | AbbVie | 2017-11-29 |
| A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma (NCT03181126) | AbbVie | 2017-11-27 |
| Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service (NCT03223012) | AbbVie | 2017-11-15 |
| Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children (NCT03339128) | AbbVie | 2017-11-15 |
| Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6 (NCT03303599) | AbbVie | 2017-11-13 |
| A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies (NCT03236857) | AbbVie | 2017-11-08 |
| A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors (NCT03311477) | AbbVie | 2017-11-06 |
| A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis (NCT03222609) | AbbVie | 2017-10-31 |
| A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan (NCT03311464) | AbbVie | 2017-10-27 |
| A Study Evaluating the Safety and Efficacy of Upadacitinib in Adults With Active Ankylosing Spondylitis (NCT03178487) | AbbVie | 2017-10-24 |
| A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab (NCT05305222) | AbbVie | 2017-10-23 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT02966756) | AbbVie | 2017-10-12 |
| A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) (NCT03234712) | AbbVie | 2017-10-10 |
| A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection (NCT03222583) | AbbVie | 2017-10-04 |
| Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection (NCT03235349) | AbbVie | 2017-09-29 |
| A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions (NCT03017014) | AbbVie | 2017-09-26 |
| A Study of SC-007 in Subjects With Advanced Cancer (NCT03253185) | AbbVie | 2017-09-13 |
| Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (NCT03271489) | AbbVie | 2017-09-13 |
| A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants (NCT05283694) | AbbVie | 2017-09-11 |
| A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China (NCT03236870) | AbbVie | 2017-09-08 |